Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $44.38.
Several equities research analysts recently issued reports on the company. Citigroup assumed coverage on Harmony Biosciences in a research note on Friday, June 21st. They set a “buy” rating and a $48.00 price objective for the company. UBS Group assumed coverage on Harmony Biosciences in a research note on Tuesday, September 10th. They set a “buy” rating and a $56.00 price objective for the company. Raymond James restated an “outperform” rating and set a $40.00 price target on shares of Harmony Biosciences in a research report on Thursday, October 10th. Mizuho raised their price target on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, October 10th. Finally, Needham & Company LLC restated a “buy” rating and set a $52.00 price target on shares of Harmony Biosciences in a research report on Wednesday, October 2nd.
View Our Latest Analysis on Harmony Biosciences
Institutional Inflows and Outflows
Harmony Biosciences Price Performance
Harmony Biosciences stock opened at $35.41 on Monday. The firm has a market capitalization of $2.01 billion, a P/E ratio of 15.33, a PEG ratio of 0.67 and a beta of 0.73. Harmony Biosciences has a one year low of $18.79 and a one year high of $40.60. The business has a fifty day moving average price of $36.41 and a 200-day moving average price of $32.83. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.13 and a quick ratio of 3.09.
Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.24. The company had revenue of $172.80 million during the quarter, compared to analyst estimates of $172.53 million. Harmony Biosciences had a return on equity of 22.97% and a net margin of 17.53%. The firm’s quarterly revenue was up 28.8% on a year-over-year basis. During the same quarter last year, the company earned $0.56 earnings per share. As a group, equities research analysts forecast that Harmony Biosciences will post 2.19 EPS for the current year.
Harmony Biosciences Company Profile
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Featured Stories
- Five stocks we like better than Harmony Biosciences
- Want to Profit on the Downtrend? Downtrends, Explained.
- Survey Reveals: America’s Most Coveted Businesses in 2024
- What is a buyback in stocks? A comprehensive guide for investors
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- How to Calculate Stock Profit
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.